Advertisement

Topics

Bellerophon Therapeutics Announces FDA Agreement On Phase IIb Study Design For INOpulse In Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

20:00 EDT 2 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Bellerophon Therapeutics Announces FDA Agreement On Phase IIb Study Design For INOpulse In Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NEXT ARTICLE

More From BioPortfolio on "Bellerophon Therapeutics Announces FDA Agreement On Phase IIb Study Design For INOpulse In Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)"

Quick Search
Advertisement